Johnson & Johnson (BSP:JNJB34)
R$ 60.12 0 (0%) Market Cap: 2.18 Til Enterprise Value: 2.27 Til PE Ratio: 24.52 PB Ratio: 5.08 GF Score: 76/100

Johnson & Johnson at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 02:15PM GMT
Release Date Price: R$53.62 (+0.06%)
Matthew Stephan Miksic
Barclays Bank PLC, Research Division - Research Analyst

Here in U.S. for Barclays. I'm very, very pleased to have with us today, J&J. From J&J, we've got Aldo Denti, Company Group Chairman of DePuy Synthes; and Peter Menziuso, Company Group Chairman of Johnson & Johnson Vision. So thanks so much, guys, for joining us today.

Aldo Denti
- Company Group Chairman of DePuy Synthes

Thank you for having us.

Questions & Answers

Matthew Stephan Miksic
Barclays Bank PLC, Research Division - Research Analyst

So I'll try to keep you both kind of engaged and busy here. We'll hop back and forth between Vision and Ortho. Maybe starting with Orthopaedics, Aldo, so I think one of the developments over the past year has been that, let's just say, after a number of years of growing kind of at a more muted growth rate, Orthopaedics, in particular, and some of your other musculoskeletal businesses have really started to kind of lift off.

So maybe can you talk about some of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot